Artal Group S.A. Xenon Pharmaceuticals Inc. Transaction History

Artal Group S.A.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$36.25 - $43.75 $4.65 Million - $5.61 Million	128,167 Added 50.58%	381,554 $14.9 Million
Q1 2024 May 13, 2024	BUY	$42.66 - $50.04 $10.8 Million - $12.7 Million	253,387 New	253,387 $10.9 Million
Q4 2018 Feb 11, 2019	SELL	$5.61 - $12.62 $1.4 Million - $3.16 Million	-250,000 Closed	0 $0
Q3 2018 Nov 09, 2018	BUY	$9.0 - $14.9 $900,000 - $1.49 Million	100,000 Added 66.67%	250,000 $3.3 Million
Q3 2017 Nov 08, 2017	BUY	$2.45 - $3.25 $367,500 - $487,500	150,000	150,000 $443,000

212

70.2M

88.3K

28.8K

Ticker XENE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,263,500
Market Cap $2.42B
Description
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.